Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS - Data support confidence in SPEARHEAD-1 as a registrational trial - - Projected to complete recruitment of all patients in Q1 2021 - - Median duration of response was 28 weeks with ongoing...

Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it...

United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the...